首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   49篇
  完全免费   2篇
  内科学   51篇
  2018年   2篇
  2017年   2篇
  2014年   1篇
  2013年   1篇
  2012年   5篇
  2011年   1篇
  2009年   4篇
  2008年   3篇
  2007年   2篇
  2006年   3篇
  2005年   3篇
  2003年   3篇
  2002年   6篇
  2001年   1篇
  2000年   1篇
  1998年   4篇
  1997年   1篇
  1996年   2篇
  1995年   3篇
  1993年   1篇
  1990年   1篇
  1980年   1篇
排序方式: 共有51条查询结果,搜索用时 31 毫秒
1.
2.
3.
Vascular development in endometriosis   总被引:8,自引:0,他引:8  
Endometriosis, defined as the presence of endometrial tissue outside the uterus, is an estrogen-dependent disease which causes pelvic pain and subfertility in women of reproductive age. The condition has a dramatic impact on the professional, social and marital life of sufferers. Direct and indirect evidence suggests that angiogenesis is required for the development and persistence of endometriosis. In this review the state-of-the-art with regard to our understanding of the role of angiogenesis in the ectopic implantation and survival of menstrual endometrial tissue will be discussed. Correspondence to: Patrick G. Groothuis, Research Institute GROW, Department of Obstetrics and Gynecology, Academisch Ziekenhuis Maastricht, Peter Debyelaan 25, 6229 HX Maastricht, The Netherlands. Tel:␣+31-43-3876625; Fax: +31-43-3876613; E-mail: patrick.groothuis@ path.unimaas.nl  相似文献
4.
行激素补充疗法的绝经后妇女子宫内膜安全性监测   总被引:5,自引:1,他引:4  
目的 探讨应用激素补充疗法(HRT)的绝经后妇女子宫内膜安全性的监测方法。 方法 对60例绝经后行HRT妇女进行血清雌二醇(E2)测定;阴道B超(TVS)监测子宫体积和子宫内膜厚度;对部分患者行子宫内膜的病理学检查和雌激素受体(ER)、孕激素受体(PR)半定量检测。 结果 应用HRT后,子宫内膜明显增厚,均值从2.8mm升至3.9mm(P<0.05);E2显著上升,由(20.6±6.9)ng/L升至(33.8±11.7)ng/L(P<0.01);子宫内膜厚度与E2呈正相关关系(r=0.94,P<0.01);20例送检内膜中,2例简单型增生过长,1例复杂型增生过长,余为萎缩型;ER(+)19例,ER(++)1例;PR均为(+)。 结论 根据临床表现,并结合血清E2和TVS检测子宫内膜厚度,可对子宫内膜安全性进行初步评估;当E2>45ng/L,子宫内膜厚度≥5mm时,则需进一步行子宫内膜病理学检查和ER测定。  相似文献
5.
Recent advances in endometrial angiogenesis research   总被引:5,自引:0,他引:5  
This review summarises recent research into the mechanisms and regulation of endometrial angiogenesis. Understanding of when and by what mechanisms angiogenesis occurs during the menstrual cycle is limited, as is knowledge of how it is regulated. Significant endometrial endothelial cell proliferation occurs at all stages of the menstrual cycle in humans, unlike most animal models where a more precise spatial relationship exists between endothelial cell proliferation and circulating levels of oestrogen and progesterone. Recent stereological data has identified vessel elongation as a major endometrial angiogenic mechanism in the mid-late proliferative phase of the cycle. In contrast, the mechanisms that contribute to post-menstrual repair and secretory phase remodelling have not yet been determined. Both oestrogen and progesterone/progestins appear to have paradoxical actions, with recent studies showing that under different circumstances both can promote as well as inhibit endometrial angiogenesis. The relative contribution of direct versus indirect effects of these hormones on the vasculature may help to explain their pro- or anti-angiogenic activities. Recent work has also identified the hormone relaxin as a player in the regulation of endometrial angiogenesis. While vascular endothelial growth factor (VEGF) is fundamental to endometrial angiogenesis, details of how and when different endometrial cell types produce VEGF, and how production and activity is controlled by oestrogen and progesterone, remains to be elucidated. Evidence is emerging that the different splice variants of VEGF play a major role in regulating endometrial angiogenesis at a local level. Intravascular neutrophils containing VEGF have been identified as having a role in stimulating endometrial angiogenesis, although other currently unidentified mechanisms must also exist. Future studies to clarify how endometrial angiogenesis is regulated in the human, as well as in relevant animal models, will be important for a better understanding of diseases such as breakthrough bleeding, menorrhagia, endometriosis and endometrial cancer. Correspondence to: Dr Jane Girling, Monash University Department of Obstetrics and Gynaecology, Monash Medical Centre, 246 Clayton Rd, Clayton, VIC 3168, Australia. Tel: +61-3-9594-5392; +61-3-9594-6389; E-mail: jane.girling@med.monash.edu.au  相似文献
6.
目的 研究雌激素不同给药方法对去卵巢大鼠子宫内膜的安全性。 方法 选用雌性大鼠 5 0只 ,随机分为 5组 :对照组、去卵巢组、已烯雌酚每天服药组、每 3d服药组及加黄体酮组。第13周对各组大鼠子宫内膜进行组织学观察及形态计量测定。 结果 去卵巢组子宫内膜萎缩、变薄 ,腺体稀少而直 ;每天组宫腔扩大 ,腺上皮细胞明显增大水肿 ;每 3d组及加黄体酮组均呈早期增生期改变。子宫内膜腺上皮细胞高度每天组 (16 2 3± 2 34) μm、每 3d组 (11 85± 0 78) μm、加黄体酮组 (12 4 0± 0 2 1) μm ,均高于去卵巢组 (7 74± 1 11) μm ,各组之间比较差异有显著性 (P <0 0 5 )。 结论 去卵巢组大鼠子宫内膜腺上皮细胞高度对雌激素较敏感 ,雌激素可改善子宫内膜萎缩状态 ,每 3d给药和加黄体酮联合给药对子宫内膜增生影响较小。  相似文献
7.
Adrenomedullin expression in the human endometrium   总被引:4,自引:0,他引:4  
Immunohistochemical studies were performed using a specific antibody to human adrenomedullin (AM) to determine its presence and cellular localization in the human endometrium, in the different phases of the menstrual cycle, and in the postmenopausal period. Specimens were obtained from 21 patients who underwent abdominal hysterectomy for various reasons. The endometrium had no pathological lesion in all cases. In the early and mid proliferative phases of the menstrual cycle, no immunostaining for AM was noted in the endometrium. AM immunostaining in the endometrium became apparent in the late proliferative phase. The staining intensity of AM in the endometrium became more abundant in the secretory phase. No appreciable difference in the staining intensity of AM in the endometrium was noted among early, mid, and late secretory phases. Immunostaining for AM was evident in both the epithelial and stromal compartments of the endometrium. In the postmenopausal endometrium, there was intense immunostaining for AM only in the stromal compartment. This is the first study to demonstrate the expression of AM in the endometrium in relation to the menstrual cycle. The results obtained suggest the participation of AM in the growth and differentiation of the endometrium.  相似文献
8.
9.
Cystic fibrosis transmembrane conductance regulator (CFTR) is a cAMP-activated Cl channel expressed in a wide variety of epithelial cells, mutations of which are responsible for hallmark defective Cl and HCO3 secretion seen in cystic fibrosis (CF). However, the physiological role of CFTR in reproductive tracts is far from understood although infertility has been observed in CF patients of both sexes. Previously we have demonstrated the expression of CFTR in the female reproductive tract and the involvement of CFTR in mediating anion secretion by the endometrium. Our recent results show that endometrial epithelial cells possess a cAMP-activated HCO3 transport mechanism, which could be impaired with channel blockers known to block CFTR or antisense against CFTR. Co-culture of sperm with CFTR antisense-treated endometrial cells or HCO3 secretion-defective CF epithelial cells resulted in reduced sperm capacitation and egg-fertilizing ability. Addition of HCO3 to the culture media and transfection of wild-type CFTR into CF cells rescued the fertilizing capacity of sperm. Immunostaining and Western blot revealed that CFTR is expressed in rodent sperm and intracellular measurement of pH during sperm capacitation indicated that the entry of HCO3 into sperm could be inhibited by CFTR inhibitor. These results are consistent with a critical role of CFTR in controlling uterine HCO3 secretion and sperm fertilizing capacity, suggesting that CFTR may be a potential target for post-meiotic regulation of fertility.  相似文献
10.
COX-2在子宫腺肌病患者子宫内膜和肌组织中的表达及意义   总被引:2,自引:1,他引:1  
田永杰  周军  沈蓉 《山东医药》2007,47(11):1-3
目的观察环氧合酶-2(COX-2)在子宫腺肌病患者子宫内膜和肌组织中的表达,探讨其意义。方法以64例手术切除子宫患者为研究对象,其中子宫腺肌病34例为观察组;子宫肌瘤30例为对照组。采用免疫组织化学方法检测COX-2在两组子宫内膜和肌组织中的表达。结果观察组增殖期和分泌期在位内膜及异位内膜COX-2阳性率均高于对照组,异位内膜高于在位内膜,P均〈0.01;异位内膜病灶周围肌层COX-2阳性率显著高于正常子宫肌层(P〈0.05);异位内膜增殖期和分泌期COX-2免疫组化评分均显著高于在位内膜,P〈0.01。结论COX-2高表达可能与子宫腺肌病的发生、发展有关。  相似文献
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号